Examining MAHA’s jump into Real World Data (RWD), and what other industry players can learn from it
MAHA's recent strategic plan announced its intent to create a comprehensive real-world data asset to fuel research. However, any desire to move from data source to insight is likely to be more complex than merely acquiring some data. What potential pitfalls could lie ahead and what can other organizations learn from this?
At a glance
Read on to get our full commentary, or use the links below to jump to a specific area of interest:
-
The RWD the HHS is looking for
-
Ok so we think we know what types of data…
-
Challenge #1: Knowing if RWD is the right fit for…
-
Challenge #2: Not doing sufficient front-end work ahead of procurement…
-
Challenge #3: Licensing and working with multiple external data vendors…
- Neat tip #1: Don’t skimp on budget if you want…
- Neat tip #2: Have a clear understanding of whether you…
- Neat tip #3: Know how vendors may react to certain…
- Neat tip #4: Know how you are going to work…
- Neat tip #5: Wade into the waters of blended assets…
- Neat Tip #6: Be wary of the emerging privacy concerns…
- Neat tip #1: Don’t skimp on budget if you want…
-
Challenge #4: Understand whether the organization is positioned to derive…
-
Closing thoughts…
-
…and a few open questions to watch for across various…
If you watched our Mid-year policy update in July, you’ll recall my co-presenter, Yulan Egan, and I discussed the MAHA report and the omission of any mention of research-ready data assets—it seemed like such a resource would be central to support plans for broad epidemiologic investigations into a variety of chronic diseases. Well, lo and behold, when the MAHA strategy document dropped on September 9, real-world data (RWD) was number two on a long list of strategic priorities, as detailed below:
Real World Data Platform (RWDP): The NIH will link multiple datasets, such as claims information, electronic health records, and wearables data, into a single integrated dataset for researchers studying the causes of, and developing treatments for, the chronic disease crisis. The RWDP will eliminate redundancies from data collection, linkage, and compute infrastructures (including artificial intelligence (AI)/machine learning and high-throughput analytics) while maintaining rigorous privacy protections and consent protections. It will also dramatically reduce administrative overhead by relying on a unified set of data use and governance agreements.
On the surface, this is an encouraging development for at least a couple of reasons. For one, the agency (the NIH specifically) is planning on gaining access to a major repository of RWD of a variety of sources and flavors, taking a page directly out of the playbook of many large pharmaceutical and medical device companies that have been leveraging RWD for roughly two decades as an increasingly routine part of their evidence generation strategy.
Union Healthcare Insight
Log in to continue reading
Not a member yet? Create a free account for limited access.
Related insights
This week in healthcare: What happened and what it means
What the 2026 midterm election results mean for healthcare policy
Healthcare policy and payment: What leaders need to know now